Home | About | Journals | Submit | Contact Us | Français |

**|**HHS Author Manuscripts**|**PMC2819808

Formats

Article sections

Authors

Related links

Am J Drug Alcohol Abuse. Author manuscript; available in PMC 2010 February 10.

Published in final edited form as:

PMCID: PMC2819808

NIHMSID: NIHMS171704

W. Scott Comulada, Dr.P.H., Robert E. Weiss, Ph.D., William Cumberland, Ph.D., and Mary Jane Rotheram-Borus, Ph.D.

Semel Institute for Neuroscience and Human Behavior and the AIDS Institute, University of California, Los Angeles, California, USA

Address correspondence to W. Scott Comulada, Dr.P.H., 10920 Wilshire Blvd., Suite 350, Los Angeles, CA 90024, USA. Email: scomulad/at/ucla.edu

The publisher's final edited version of this article is available at Am J Drug Alcohol Abuse

See other articles in PMC that cite the published article.

ZIP models were used to detect reductions in drug abuse among young people living with HIV (YPLH) over 15 months when most young people abstain from use. YPLH (n = 171) aged 16 to 29 years were randomly assigned to an 18 session intervention or a delayed-intervention condition. The ZIP models showed significant reductions in abuse of multiple substances over time in the non-delayed intervention. Previous analyses did not find significant reductions. Intervention efficacy often cannot be detected if there are highly skewed distributions of outcomes, such as drug abuse. ZIP modeling offers an opportunity to more reliably detect behavioral changes.

Prevention for HIV + persons is a top priority for the Centers for Disease Control and Prevention (1). We previously demonstrated that when young people living with HIV (YPLH) attended a three-module intervention delivered in small groups (Teens Linked to Care [TLC]) (2, 3) or in individual sessions (Choosing Life, Empowerment, Action, and Results [CLEAR]) (4), the YPLH reduced their unprotected sexual acts. Drug abuse was an entry criterion for this study. Therefore, all participants were active users at the time of recruitment. When using logistic regression analyses that examined only reductions in use (4), we did not find significant reductions in drug use as a function of the intervention. The current analysis evaluates a different, more powerful analytic strategy that allows the simultaneous examination of both elimination of use of a specific drug (a yes-no event) and reductions in use over time. In this article we re-examine the effects of the intervention on drug abuse, considering the impact of the highly skewed distributions in the reports of drug use by young people.

YPLH use a broad range of drugs: e.g., marijuana, cocaine, methamphetamine, heroin, and ketamine (2, 5). In a typical sample of substance-using young people, most young people do not use each drug. Thus, if we analyze the impact of reducing drug use from *use* to *non-use*, a very high proportion of participants will be non-users. Table 1 demonstrates that there is zero-inflation in the reports of drug use at baseline among YPLH in the CLEAR intervention (5). The usage distribution is very skewed.

Given these distributions, standard regression techniques are inadequate for analyzing the outcomes, in this case, the impact of an intervention case management approach on reducing drug abuse. When analyzing drug use, both binomial (*use/non-use*) and count data are combined in these distributions. To more sensitively examine the impact of an intervention on drug use, we utilize longitudinal zero-inflated Poisson (ZIP) models (6, 7) to examine reductions of the frequency of use among drug users.

From 1999 to 2002, 253 YPLH aged 16 to 29 (median age = 23) were voluntarily recruited to participate in a cognitive behavioral HIV transmission-reduction intervention trial, mostly from medical providers and social service agencies in Los Angeles, San Francisco, and New York. We had an eligibility criterion of using alcohol or illicit drugs at least 5 times in the last 3 months to coincide with the study aim of reducing transmission acts among substance users. Seventy percent of those recruited (n = 176/253) were eligible and randomized into one of two immediate intervention conditions (telephone or in-person), or a delayed condition. Analyses were conducted on the 171 YPLH not missing substance use information at baseline. YPLH were interviewed at baseline, 3, 6, 9, 15, and 21 months through a computerized assessment. YPLH in the delayed condition received the in-person intervention after the 15 month interview. Details may be found in previous publications on CLEAR (4, 5).

Most YPLH included in analyses are bisexual or gay males (69%; 9% heterosexual males and 22% females), Black (27%) or Latino (43%), and had no AIDS diagnosis (77%); about half reported experiencing HIV symptoms (56%). At baseline, self-reported substance use rates over the past three months were 21% for cocaine, 11% for crack, 6% for heroin, 14% for inhalants, 67% for marijuana, 27% for methamphetamines, and 15% for stimulants/amphetamines. We exclude heroin use from our analyses due to low rates of use.

YPLH reported the number of days using in the past 3 months and the average number of times used per day for cocaine, crack, heroin, inhalants, marijuana, methamphetamines, and stimulants/amphetamines. Frequency of use was estimated by multiplying the number of days in the past 3 months used by the average number of times used per day. We considered reports of using any substance 5 times a day by 90 days (equaling 450 times) or more to be outliers and Windsorized (8) 28 marijuana outliers and 20 outliers across the remaining drugs by replacing their values with 450.

A validation study to assess over-reporting of use was conducted on 82 of the participants whose reported substance-use frequency exceeded 4 times in the past 3 months at baseline. Urine samples were collected and compared to reported use. Thirty-three percent of those testing positive for cocaine metabolites had reported cocaine or crack use (Kappa = .31); 84% of those testing positive for marijuana had self-reported marijuana use; 83% of those testing positive for amphetamine had reported amphetamine use (Kappa = .76). A Kappa of .31 suggests poor agreement between self-reported and urine-sample test results for cocaine and crack use.

We conducted intent-to-treat analyses and examined the intervention effect on each substance use frequency measure from baseline to 15 months post randomization. The frequency of use is visibly zero-inflated across all substances. The percentage of zeros is shown in Table 1 for the frequency of use for each drug at baseline. Similar patterns are seen at other time points. At least half of the subjects were reported non-users for each substance across all time points.

Inappropriate statistical models such as standard Poisson regression models, which assume a Poisson distribution for the frequency of use outcome, may lose power to determine an intervention effect. Erroneous statistical assumptions usually inflate the variance, causing reduced power to identify intervention effects. For example, an intervention may impact substance users through two mechanisms: users may be influenced to become non-users, and they may reduce use frequency. An intervention effect may be masked if the intervention only influences participants to become non-users but does not reduce substance use among participants who remain substance users, or vice versa.

The longitudinal Zero-inflated Poisson (ZIP) model (6, 7) allows the two mechanisms of the intervention effect to be explored in the presence of zero-inflated count data. A zero is allowed to come from two processes: one process, with probability p, the zero or ‘‘non-user’’ state, has zeros as the only possibility, and the other process, with probability 1-p, has Poisson distributed counts which could in turn be zero, e.g. counts from substance users who were not using when the data were collected. The non-user state is modeled via a logistic regression and the Poisson distributed counts are modeled via a Poisson regression conditional on counts not being in the non-user state.

We fit longitudinal ZIP models to each substance use frequency measure over time, from baseline to 15 months, to estimate intervention effects. Covariates in the logistic and Poisson regressions include an intercept, intervention condition indicators (Telephone and In-person), months from baseline interview (Time), and time by intervention indicator interactions to assess the change in slope between intervention conditions over time. Demographic covariates for gender and ethnicity included in the original analyses are included in the Poisson regression, as well as a random effect for each person. Analyses are conducted in a Bayesian framework using WinBUGS version 1.4.1 software (9). Posterior means (*M*) and standard deviations (*SD*) of model parameters are reported and equivalent to parameter estimates and standard errors from a frequentist analysis. Ninety-five percent posterior intervals (95% PI) are also reported for key significant results and range from the 2.5th to the 97.5th percentiles of the posterior densities they are covering.

We plot estimated mean substance use counts over time from the ZIP model results. The ZIP model assumes that a substance use count outcome is the product of a Bernoulli random variable modeled with a logit link and a Poisson modeled with a logarithmic link. As given by Lambert (6), the mean count outcome c_{ij} is estimated as c_{ij} = exp(β_{ij})/(1+exp(α_{ij})), where ‘‘exp’’ is the base *e* exponential transformation, α_{ij} is the linear predictor from the logistic regression, and β_{ij} is the linear predictors from the Poisson regression for person i at time point j. Random effects are drawn from the predictive posterior density and incorporated into β_{ij} using a parametric version of the smearing estimate (10). An estimate at time point j of the mean substance usage is the median of the c_{ij} calculated for each person and set of draws from the joint posterior of the parameter estimates and random effects.

Parameter estimates from the ZIP model are given in Table 2 and 95%PI are reported for significant intervention by time parameters from the Poisson part of the model. The intervention did not significantly impact conversion to substance non-use, as indicated by the logistic results, but did impact usage among users, i.e., participants not in the zero state, as indicated by the Poisson results. Among users, reductions over time in the in-person and telephone conditions compared to the delayed condition were seen in the frequency of use for crack (95% PI = −.33 to −.09 and −.86 to −.54, respectively), marijuana (95% PI = −.11 to −.02 and −.19 to −.08, respectively), and methamphetamines (95% PI = −.60 to −.34 and −.59 to −.39, respectively). Reductions were also seen for stimulants (95% PI = −1.20 to −.46) in the telephone condition and for inhalants (95% PI = −2.14 to −1.32) in the in-person condition compared to the delayed condition. Among users, increases were seen in the frequency of cocaine use in the in-person (95% PI = 2.41 to 2.97) and telephone (95% PI = 1.28 to 1.93) conditions compared to the delayed condition.

Posterior means (M) and standard deviations (SD) of parameters estimated from longitudinal ZIP model fit to frequency of substance use measures. Poisson part of model adjusts for gender and ethnicity. Logistic regression models probability of being in **...**

Estimated counts during the past three months for each of the seven substances are plotted in Figure 1. The trajectories for cocaine use in the in-person and telephone conditions are fairly flat, showing the positive time by intervention slope coefficient is due more to a decrease over time in the trajectory of the delayed condition. The fairly large baseline differences in substance use counts relative to trajectories over time are consistent with earlier findings (4), which found the delayed condition to be more sexually risky at baseline compared to the in-person and telephone conditions.

Outcome analyses examining the impact of a prevention case management intervention for YPLH demonstrated very different results when a two-step analytic procedure was implemented. In contrast to the findings with random linear regression models, we were able to examine the impact of the intervention of seven specific classes of drugs (cocaine, crack, heroin, inhalants, marijuana, methamphetamine, and stimulants). The binomial outcomes of *use/non-use* were not significantly reduced in the intervention condition: there were significant increases over time in the use of marijuana, methamphetamine, and stimulants over the course of the study (regardless of intervention status) and a significant increase in the in-person case management intervention of crack use. These findings are consistent with developmental patterns in substance abuse for young adults, particularly those with a history of drug abuse. Rates of substance abuse increase until the early 20s (11, 12).

When we examined the impact of intervention condition on the frequency of use among users, we found significant relationships between reductions in use and the intervention condition. Both the telephone and the in-person condition significantly reduced crack, marijuana, and methamphetamines compared to the delayed condition. Reductions were also seen for heroin and stimulants in the telephone condition and for inhalants in the in-person condition compared to the delayed condition. However, cocaine use was significantly lower among young people in the delayed control condition compared to the intervention condition. These findings favor the intervention condition for five of seven drugs. There is no clear explanation for the increase in cocaine use among those in the intervention condition compared to the delayed condition. Future research will have to examine this unexpected outcome.

The methodology for reanalyzing these results has the potential to redirect analyses of substance abuse outcomes for many intervention trials. The zero-inflation problem in the distribution of substance abuse is common. Changing from a user to a non-user is different from reducing frequency of use. ZIP analyses are common in biomedical research (7, 13–15). While they have been used in substance abuse research (16, 17), they are underutilized. We encourage experimentation by other researchers in the future.

This research was supported by Grant R01 DA-07903 from the National Institute on Drug Abuse.

**Publisher's Disclaimer: **Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article maybe used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

1. Centers for Disease Control and Prevention. HIV=AIDS Surveillance Report. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention 2005; 2004. Also available at: http://www.cdc.gov/hiv/stats/hasrlink.htm.

2. Rotheram-Borus MJ, Lee M, Murphy D, Futterman D, Duan N, Birnbaum JM, Lightfoot M. Teens Linked to Care Consortium Efficacy of a preventative intervention for youths living with HIV. Am J Public Health. 2001;91:400–405. [PubMed]

3. Rotheram-Borus MJ, Lee M, Zhou S, O’Hara P, Birnbaum JM, Swendeman D, Wright W, Pennbridge J, Wight RG. Teens Linked to Care Consortium Variation in health and risk behavior among youth living with HIV. AIDS Educ Prev. 2001;13(1):42–54. [PubMed]

4. Rotheram-Borus MJ, Swendeman D, Comulada WS, et al. Prevention for substance using HIV positive young people: Telephone and in-person delivery. J Acquir Immune Defic Syndr. 2004;37:S68–S77. [PMC free article] [PubMed]

5. Comulada WS, Swendeman DT, Rotheram-Borus MJ, et al. Use of HAART among young people living with HIV. Am J Health Behav. 2003;27(4):389–400. [PMC free article] [PubMed]

6. Lambert D. Zero-inflated Poisson regression with an application to defects in manufacturing. Technometrics. 1992;34:1–14.

7. Hall D. Zero-inflated Poisson and binomial regression with random effects: A case study. Biometrics. 2000;56:1030–1039. [PubMed]

8. Barnett V, Lewis T. Outliers in Statistical Data. New York: John Wiley & Sons; 1978.

9. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS Version 1.4 User Manual. Cambridge, UK: MRC Biostatistics Unit; 2003.

10. Duan N. Smearing estimate: A nonparametric retransformation method. J Am Stat Assoc. 1983;78:605–610.

11. Substance Abuse and Mental Health Services Administration (SAMHSA) Substance Abuse and Mental Health Services Administration. Rockville, MD: U.S. Dept. of Health and Human Services Publication SMA 00-3466; 2000. Summary Findings from the 1999 National Household Survey on Drug Abuse.

12. Johnson RL. Drug abuse. Pediatr Rev. 1995;16(5):197–199. [PubMed]

13. Choi L, Dominici F, Zeger SL, Ouyang P. Estimating treatment efficacy over time: A logistic regression model for binary longitudinal outcomes. Stat Med. 2005;24(18):2789–2805. [PubMed]

14. Lee AH, Wang K, Scott JA, Yau KK, McLachlan GJ. Multi-level zero-inflated Poisson regression modelling of correlated count data with excess zeros. Stat Methods Med Res. 2006;15(1):47–61. [PubMed]

15. Nie L, Wu G, Brockman FJ, Zhang W. Integrated analysis of transcriptomic and proteomic data of Desulfovibrio vulgaris: Zero-inflated Poisson regression models to predict abundance of undetected proteins. Bioinformatics. 2006;22(13):1641–1647. [PubMed]

16. Stormshak EA, Comeau CA, Shepard SA. The relative contribution of sibling deviance and peer deviance in the prediction of substance use across middle childhood. J Abnorm Child Psychol. 2004;32(6):635–649. [PubMed]

17. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. Targeted versus daily Naltrexone: Secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006;30(5):860–865. [PubMed]

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's Canada Institute for Scientific and Technical Information in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers. |